About
AEYE-DS is FDA 510(k)-cleared for autonomous DR screening (Nov 2022) and, in 2024, became the first fully autonomous AI cleared on a handheld camera (Optomed Aurora) — aimed at point-of-care screening beyond the eye clinic.
HQ: New York, USA (founded Tel Aviv, 2018)
Funding
~$16M Series A reported (BlackRock, Fin Capital); totals vary $10M–$28M across databases
Funding figures conflict across databases; treat as unverified.